Affiliations: Abteilung für klinische Hämostaseologie und Transfusionmedizin, Universität des Saarlandes, D-66421 Homburg/Saar | Institut für Transfusionsmedizin und Immunhämatologie, Universitätsklinikum Charité, D-10098 Berlin | Laevosan-Gesellschaft mbH, Estermannstraße 17, A-4021 Linz
Abstract: In an open Phase-II study on 10 patients with POAD II the plasmatic elimination, rheological and hemostasiological parameters of a new hydroxyethyl starch with a mean molecular weight of 100,0000 Dalton, a molar substitution of 0.5 and a C2/C6 substitution ratio of 6.2 (HES 100/0.5) were determined. Measurements were carried out before and 1, 3, 6, and 24 h after infusion. The mean molecular weight of 100,000 Dalton decreased only slightly up to 24 hours. The plasmatic molecular distribution width of the HES 100/0.5 was unchanged during the whole period of time - in contrary to other HES-types. The decrease in the hematocrit of 5.5% is comparable to other HES-types, and is still significant up to 24 h after infusion. Similar effects can be seen for the plasma viscosity. The decrease is about 3% which is still significant 24 h after infusion (from 1.33 mPas to 1.28 mPas after 24 h). The maximal decrease of erythrocyte aggregation is about 26% (from 23 to 18 one hour after infusion), and this effect is still significant 24 h after infusion. Plasmatic haemostasis is not influenced by hemodilution treatment with HES 100/0.5; prothrombin time and partial thromboplastin time remained unchanged. The amount of rheological changes is comparable to HES 200/0.5 whilst the improvement of blood fluidity is lasting longer. The lack of influence on plasmatic hemostasis could offer advantages from a hemostasiological point of view. HES 100/0.5 seems to be an interesting variant of a known and proven colloid which however has to be evaluated in further clinical biometrically stringent studies.
